ArticleBritish journal of cancer2007
Further observations on the relationship between the FGFR4 Gly388Arg polymorphism and lung cancer prognosis.
Article in British journal of cancer, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Effect of Lenvatinib on a Hepatocellular Carcinoma with Fibroblast Growth Factor Receptor 4 Expression: A Case Report and Review of the Literature.Internal medicine (Tokyo, Japan) · 2021Review
- FGFR4 Gene Polymorphism Reduces the Risk of Distant Metastasis in Lung Adenocarcinoma in Taiwan.International journal of environmental research and public health · 2020Article
- FGF19-Cells · 2019Review
- Fibroblast growth factor receptor 4 single nucleotide polymorphism Gly388Arg in head and neck carcinomas.World journal of clinical oncology · 2019Article
- bFGF Protects Against Oxygen Glucose Deprivation/Reoxygenation-Induced Endothelial Monolayer Permeability via S1PR1-Dependent Mechanisms.Molecular neurobiology · 2018Article
- The FGFR4-388arg Variant Promotes Lung Cancer Progression by N-Cadherin Induction.Scientific reports · 2018Article
- Prognostic significance of fibroblast growth factor receptor 4 polymorphisms on biochemical recurrence after radical prostatectomy in a Chinese population.Scientific reports · 2016Article
- FGF23 from bench to bedside.American journal of physiology. Renal physiology · 2016Review
- Is fibroblast growth factor receptor 4 a suitable target of cancer therapy?Current pharmaceutical design · 2014Review
- Deficiency of metabolic regulator FGFR4 delays breast cancer progression through systemic and microenvironmental metabolic alterations.Cancer & metabolism · 2013Article
- [Advanced research of fibroblast growth factor receptor in non-small cell lung cancer].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2013Review
- Fibroblast growth factor receptor 4 Gly388Arg polymorphism in Chinese gastric cancer patients.World journal of gastroenterology · 2013Article
- Targeted agents in non-small cell lung cancer therapy: What is there on the horizon?Journal of carcinogenesis · 2013Article
- Differential effects of polymorphic alleles of FGF receptor 4 on colon cancer growth and metastasis.Cancer research · 2012Article
- Loss of heterozygosity and DNA methylation affect germline fibroblast growth factor receptor 4 polymorphism to direct allelic selection in breast cancer.The American journal of pathology · 2010Article
- Article
- Genetic variants in FGFR2 and FGFR4 genes and skin cancer risk in the Nurses' Health Study.BMC cancer · 2009Article
- Association of FGFR4 genetic polymorphisms with prostate cancer risk and prognosis.Prostate cancer and prostatic diseases · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Gly388Arg polymorphism in the fibroblast growth factor receptor 4 (FGFR4) gene has been reported to influence prognosis in a wide variety of cancer types. To determine whether Gly388Arg is a marker for lung cancer prognosis, we genotyped 619 lung cancer patients with incident disease and examined the relationship between genotype and overall survival. While we employed a comprehensive set of statistical tests, including those sensitive to the detection of differences in early survival, our data provide little evidence to support the tenet that the FGFR4 Gly388Arg polymorphism is a clinically useful marker for lung cancer prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.